Novo’s Wegovy successor disappoints in second large trial – BioPharma Dive
Novo’s Wegovy successor disappoints in second large trial BioPharma Dive
Novo Nordisk shares fall on weight-loss drug trial – MSN
Novo Nordisk shares fall on weight-loss drug trial MSN
Novo Nordisk shares fall on weight-loss drug trial – Fox Business
Novo Nordisk shares fall on weight-loss drug trial Fox Business
IA-2A positivity identified as a key predictor in type 1 diabetes progression
A recent study published in Diabetologia has identified insulinoma-associated protein 2 autoantibody (IA-2A) positivity as a…
Novo Nordisk shares fall on weight loss drug trial results – Proactive Investors USA
Novo Nordisk shares fall on weight loss drug trial results Proactive Investors USA
Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain. – Barron’s
Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain. Barron’s
Roche announces hub for cardiovascular, renal and metabolism research
Roche has announced the launch of the Roche Genentech Innovation Center Boston, which will serve as…
Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says – TradingView
Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says TradingView
Novo Nordisk stock sinks on weight loss drug trial letdown – Yahoo Finance
Novo Nordisk stock sinks on weight loss drug trial letdown Yahoo Finance